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Abstract | In the 50 years since Andreas Rett first described the syndrome that came to 
bear his name  and now known to be caused by a mutation in the methyl-CpG-binding 
protein 2 (MECP2) gene, a compelling blend of astute clinical observations and clinical and 
laboratory research has substantially enhanced our understanding of this rare disorder. 
Here, we document the contributions of the early pioneers in RTT research, and describe 
the evolution of knowledge in terms of diagnostic criteria, clinical variation, and the 
interplay with other Rett-related disorders. We provide a synthesis of what is known about 
the neurobiology of MeCP2, considering the lessons learned from both cell and animal 
models, and how they might inform future clinical trials. With a focus on the core criteria, 
we examine the relationships between genotype and clinical severity. We review current 
knowledge about the many comorbidities that occur in RTT, and how genotype may modify 
their presentation. We also acknowledge the important drivers that are accelerating this 
research programme, including the roles of research infrastructure, international 
collaboration and advocacy groups. Finally, we highlight the major milestones since 1966, 
and what they mean for the day-to-day lives of individuals with RTT and their families. 
 
Introduction 
In 1966, Andreas Rett first reported on a series of 22 young female patients with similar 
characteristics. He was initially alerted to their similarities when he observed two of the 
group sitting together in his waiting room, demonstrating almost identical stereotypic hand 
movements1 (FIG. 1), and so the gestalt of Rett syndrome (RTT) was first recognized. RTT 
was initially thought to be of metabolic origin because of an apparent association with 
hyperammonaemia, but this idea was later discounted because of laboratory error. 17 years 
later, Bengt Hagberg and colleagues attributed Rett’s name to the condition that they had 
also seen in their patients2. The disorder affected girls, who initially seemed to develop 
normally, but began to lose their previously achieved abilities — in particular, hand use and 
speech — at 7–18 months of age (or sometimes later, as has subsequently been shown3). 
Our aim in this Review is to describe the 50-year journey from the recognition of RTT 
to the present day, a journey that has included iterations of the diagnostic criteria and 
growing understanding of the clinical and biological variation of the disorder. We focus 
particularly on the discovery that RTT is caused by a mutation on the MECP2 gene, the 
burgeoning knowledge of its neurobiology, and ensuing pathways to clinical trials. We 
include a detailed review of the phenotype and observed relationships with genotype, and 
reflect on how knowledge of RTT has advanced rapidly, in part due to database 
infrastructure, international collaborations and strong advocacy groups. 
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Pivotal discoveries and advances 
The original description of RTT by Hagberg and colleagues2 (FIG. 1) was followed by an 
explosion of literature about the disorder, much of which was published as proceedings of 
early meetings held in Vienna and Baltimore.  
An important outcome of the first Vienna symposium was the need for a set of clinical 
criteria to facilitate diagnosis (FIG. 1), and a schema of clinical characteristics with eight 
inclusionary and four exclusionary criteria was published soon afterwards4. Over the past 
three decades, these criteria have undergone several iterations5–7.  
The international workshop held in Baltimore was co-sponsored by a newly formed parent 
organization, the International Rett Syndrome Association, and was attended by over 85 
health-care professionals, along with 70 girls with RTT and their families. This workshop was 
the beginning of a close collaboration between parents and researchers, which has 
contributed greatly to the rapid advancement of knowledge in this condition. A case series 
that emerged as a consequence was seminal in informing the medical community about the 
clinical features of this disorder8, as was the description of 19 cases in the west of Scotland9.  
A staging system, which characterized the disease profile into four distinct phases, was 
developed from information relating to 29 Swedish cases 10. On the basis of citation history, 
this system seems to have been widely adopted but, as has not yet been formally validated 
in the light of the currently available genetic knowledge and longitudinal data.  
The pivotal discoveries that followed on from the original clinical revelations are outlined 
in FIG. 1, and their enormous significance will become clear as we follow the story of RTT — 
in the laboratory, in the clinic and across the world — over a further three decades. 
 
Identifying the genetic cause of RTT 
The relationship between the MECP2 gene and RTT was discovered in the Zoghbi laboratory 
in 1999 (REF. 11) (FIG. 1). This crucial milestone was reached as a consequence of preceding 
exclusion mapping studies, which had narrowed down the area of interest on chromosome 
Xq28 (REFS 12,13). The nuclear protein MeCP2 had hitherto been of interest largely in the 
field of epigenetics, and the finding that MeCP2 lay at the root of RTT resulted in a 
convergence of clinical, neuroscience and epigenetics researchers to begin to understand 
the disease process. 
This momentous discovery had two immediate sequelae, the first being its impact on 
research. A second study from the Zoghbi laboratory identified a MECP2 mutation in just 
over three-quarters of screened patients with sporadic RTT, and in two of seven familial 
cases14. Severity was scored from previous clinical observations, and mutations were 
categorized as either truncating or missense. Although non-random X-inactivation also 
affected the phenotype, no overall genotype–phenotype relationships were identified at 
this stage 14. However, this was just the first of numerous such investigations that were 
conducted across the globe in the ensuing years15–18. One of the earliest papers identified 
MECP2 mutations in 80% of typical RTT cases18. These included eight recurrent missense 
and nonsense mutations, which are now known to account for almost two-thirds of the 
mutations seen in RTT19,20 (FIG. 2). 
The second consequence of Zoghbi’s findings was the burgeoning availability of 
genetic testing, at least in European countries with equitable public funding systems, and 
for appropriately insured patients in the USA. Sadly, however, genetic testing remains 
inaccessible to patients in many countries. Techniques other than direct sequencing, such as 
multiplex ligation-dependent probe amplification (MLPA), which is necessary for the 
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identification of large deletions of exon 3 and 4 (REFS 21,22), have also become available. 
Such developments would have major implications for the subsequent identification of 
these mutation types. 
 
Neurobiology of MeCP2 
RTT is not considered to be a degenerative brain condition, but patients with this condition 
exhibit reductions in gross brain volume, which are associated with the presence of 
abnormally small, densely packed neurons with reduced dendritic complexity and synapse 
density23. The discovery, in 1999, that genetic lesions in the MECP2 gene represent the 
underlying cause of RTT11 dramatically intensified efforts to model the disorder biologically. 
 
MeCP2 is essential for normal brain function. Much of the work on MeCP2 has relied on 
patient-derived cells24–28 and genetically modified mice, including Mecp2-knockout lines29,30 
(FIG. 1), as well as a variety of conditional knockout lines in which the gene has been 
deleted from specific brain regions or brain cell types30–38, or at different stages of 
development39. This work has shown that loss of MeCP2 disrupts the given brain region or 
system from which it is deleted, and that localized disruption results in a subset of the 
commonly observed symptoms of RTT. Deletion from GABAergic circuits, which are 
ubiquitous across brain systems, produces a near-complete Mecp2-null phenotype, 
including motor and cognitive impairments32. By contrast, deletion from glutamatergic cells 
causes anxiety and tremor40. Interestingly, postnatal deletion of Mecp2, even within a 
mature nervous system, results in RTT-like phenotypes41,42.  
In mouse models, activation of a previously silenced Mecp2 allele globally, or within 
GABAergic neurons, reverses many established RTT-like phenotypes, including locomotor, 
behavioural and aberrant functional and structural synaptic plasticity43–45 (FIG. 1). This 
finding suggests that many of the features that characterize an RTT-like disorder in mice are 
amenable to reversal, but also indicates that RTT is not a straightforward 
neurodevelopmental disorder, and MeCP2 has an essential and ongoing role in the mature 
nervous system. These observations have important implications when considering 
potential therapeutic interventions. An important caveat in interpreting the mouse data is 
that hemizygous (Mecp2-/y) null male mice are frequently used experimentally, owing to 
their more overt and rapidly apparent phenotypes. One should note, however, that 
heterozygous (Mecp2+/–) female mice are the most accurate genetic representation of most 
patients with RTT, despite the fact that they develop overt phenotypes at a much later 
developmental time point than do humans.  
MeCP2 is especially abundant in postmitotic neurons46,47, but is also expressed at 
modest levels in non-neuronal cells in the brain48,49 and in other tissues throughout the 
body50,51. Deletion of Mecp2 from glia in mice has relatively minor phenotypic 
consequences, but restoration of MeCP2 to astrocytes in an otherwise MeCP2-deficient 
nervous system results in partial amelioration of phenotypes, including normalization of 
breathing patterns, motor activities and anxiety levels48. As also indicated in primary culture 
experiments52, MeCP2 in glial cells might contribute to certain non-cell-autonomous 
functions, such as supporting normal dendritic morphology through the release of trophic 
factors within the nervous system. However, a lack of functional MeCP2 in neurons is 
generally considered to be the dominant driver of RTT53. 
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MeCP2 in non-neural cells. The relative importance of MeCP2 in peripheral tissues is 
unclear. The consequences of global MeCP2 deficiency are observed in several peripheral 
systems, and they include fatty liver and metabolic disease54, lung lesions55, cardiac 
effects56,57, and aberrant bone phenotypes58,59. Selective deletion of Mecp2 in hepatocytes 
did not recapitulate metabolic dysfunction (insulin resistance, glucose tolerance, altered 
circulating fatty acids) or overt neurological effects 54 seen in in knockout mice but did 
recapitulate the fatty liver seen in some Mecp2-null lines, possibly reflecting a phenotype 
with a genuine peripheral origin. Evidence has also been obtained for altered bone cell 
regulation in MeCP2-deficient osteocytes60, probably explaining the osteoporotic 
phenotypes described in RTT. By contrast, no changes have been observed in skeletal 
muscle following selective local Mecp2 deletion61.  
Overall, MeCP2 depletion studies have revealed that the majority of RTT-like 
behavioural, sensorimotor and autonomic phenotypes are associated with MeCP2 
deficiency in the brain. However, some less extreme but still clinically significant aspects of 
the disorder may arise independently of defects in the nervous system51. 
 
MECP2 mutations and protein function. The structure and function of MeCP2 protein have 
been reviewed in detail elsewhere39,62. The two known protein isoforms of MeCP2 differ 
only at the extreme N-terminus and, despite some evidence for isoform-specific functions63, 
the two forms are considered to be largely functionally equivalent53,64 although MeCP2_e1 
is the dominant brain isoform. MeCP2 was originally discovered as a result of a biochemical 
screen for factors that interact with DNA, in particular, with methylated cytosines (within 
the context of CpG sequences)65. MeCP2 is a nuclear protein that tracks DNA methylation by 
virtue of its methyl-CpG-binding domain (MBD)66. Emerging evidence suggests that the MBD 
of MeCP2 does not exclusively interact with CpG dinucleotides, but also has an affinity for 
methylated CpA67. The MBD is also reported to interact with 5-hydroxymethylcytosine-
containing DNA68,69, and these modified DNA sequence contexts might be of special 
importance in the brain70. The importance of the MBD is highlighted by the fact that 
pathogenic missense mutations in this region cause reduced binding to methylated DNA71. 
Regions distinct from the MBD, including AT-hooks72 and a basic cluster73, have also been 
implicated in DNA binding. The functional importance of these regions remains to be fully 
established, but it is possible that together with the MBD, they contribute to chromatin 
structure. 
A presumed major function of MeCP2 is to regulate gene expression at either a local 
or a global level. DNA methylation is a modification that is linked to gene silencing, and a 
long-held view is that MeCP2 is important in transcriptional repression74. However, MeCP2 
has also been linked to gene activation75. MeCP2 interacts with a wide range of proteins39, 
including the histone deacetylase co-repressor complexes SIN3A, NCOR (nuclear receptor 
co-repressor) and SMRT (also known as NCOR2)76–79. The NCOR–SMRT interaction domain 
(NID) has been mapped within the wider transcriptional repression domain (TRD) of MeCP2, 
and a cluster of RTT-causing missense mutations, including the common Arg306Cys variant, 
have been shown to disrupt this interaction71 (FIG. 2). These findings have led to the idea of 
a bridge model, whereby MeCP2 functions as a tether between DNA and the NCOR–SMRT 
complex, and missense mutations at either end of the bridge will result in RTT71. Recent 
reports suggest that MeCP2-associated transcriptional regulation is preferentially targeted 
to long genes, which might be important in the downstream cellular pathologies80,81. 
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In addition to the repressor model of MeCP2 function, a number of alternative or 
overlapping functions have been ascribed, including direct roles in chromatin remodelling 
(compaction)82, gene activation75, regulation of alternative splicing83,84, and microRNA 
(miRNA) processing85. In turn, MeCP2 function can be regulated by miRNAs86,87 and activity-
dependent phosphorylation88,89. The relevance of this latter mechanism to RTT is unclear, as 
no RTT-causing point mutations have been reported within known MeCP2 phosphorylation 
sites. The level of MeCP2 within a given cell type is believed to be crucial for normal cellular 
homeostasis, and both loss of function and overexpression have neurological 
consequences53,90–92. MECP2 Duplication syndrome, the clinical manifestation of 
overexpression, is more commonly reported in males91,93, and its phenotype is gradually 
being delineated. When modelled in mice, MECP2 duplication syndrome, like RTT, has 
shown the potential for phenotypic reversal when MeCP2 levels are restored to normal94. 
Loss of MeCP2 alters the cellular levels of many gene products, but the effects at the 
individual gene level are typically small75,95, and are likely to be cell-type-specific. The fact 
that a wide variety of genes are affected suggests that the existence of a single pathogenic 
pathway that can act as a focus for all therapeutic interventions is unlikely. Downstream, 
many cellular systems are disrupted, and there have been reports of altered synaptic 
function and plasticity43,96–100, reduced protein synthesis101, impaired mitochondrial 
function102, oxidative stress103, and alterations in various signalling and homeostatic 
pathways, such as the mTOR–AKT pathway101 and energy and lipid metabolism54. The 
relative importance of these effects to cellular dysfunction may depend on the type and 
state of the cell. 
 
Clinical features and diagnosis 
Diagnosis of Rett syndrome and related disorders: evolution over time. Until 1999, RTT 
remained solely a clinical diagnosis, based initially on the Vienna criteria4, and subsequently 
on modifications made by a US group5 (FIG. 1). The modifications included a slight 
expansion of the exclusion criteria, and the addition of a set of supportive criteria relating to 
breathing dysfunction, peripheral vasomotor disturbances, seizures, scoliosis, growth 
retardation and small feet. 
The revised diagnostic criteria were initially restricted to include only classic cases of 
RTT (BOX 1), with the intention of providing a homogenous patient population for 
epidemiological research104. Subsequently, it was recommended that cases not fulfilling all 
the necessary criteria should be designated as atypical105. In Europe, the term ‘variant’ was 
used to describe a range of Rett-like phenotypes that were categorized as atypical in other 
regions. These phenotypes included forme fruste (BOX 2), congenital forms, infantile seizure 
onset106 male, late childhood regression and preserved speech variants107. Subsequently, a 
model to categorize atypical RTT in “a girl with unspecified mental retardation, aged 10 
years or more” was developed, and required the presence of three or more primary criteria 
and five or more supportive criteria108 (BOX 2; FIG. 1). The purpose of this model was to 
cover the full range of clinical manifestations that are likely to be encompassed by the 
underlying biological disorder, which was subsequently revealed by the discovery of the 
true genetic cause of RTT11 (FIG. 1).  
At a meeting in Baden-Baden in 2001, the existing three sets of criteria4,5,108 were 
assessed and combined to form two new versions, one for classic RTT (BOX 1) and one 
recognizing atypical RTT (BOX 2) as its own entity6 (FIG. 1). The new criteria reflected some 
additional lessons that had been learned since the formulation of the previous criteria, such 
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as the fact that early development was not invariably normal109, and that head growth did 
not always decelerate110. 
In 2010, a further set of criteria was introduced in the hope of clarifying some of the 
differences in terminology between Europe and North America7 (FIG. 1). In contrast to 
previous iterations, and in addition to the four core criteria relating to loss of hand skills, 
loss of spoken language, gait abnormality and stereotypic hand movements, a mandatory 
criterion of a period of regression followed by recovery or stabilization was introduced. For 
atypical RTT, a period of regression was also mandatory, but only two of the four criteria 
were required, along with at least five of eleven supportive criteria.  
One may question the need for the additional regression criterion, given that 
regression in some patients is often described as “fleeting or unrecognized”111, or may not 
yet have occurred at the time of genetic testing, which is now widely used by clinicians 
diagnosing RTT. Although dependence on clinical criteria without genetic confirmation is 
necessary in some parts of the world, in many developed countries direct sequencing is 
being replaced by a range of next-generation sequencing techniques, including targeted 
gene sequencing, whole-exome sequencing and whole-genome sequencing. Consequently, 
molecular testing for children with developmental problems could be undertaken at an 
early age before the hallmark features that characterize particular disorders have become 
apparent. These technological advances may eventually prove to be more efficient and cost-
effective for diagnosis112, and the RTT clinical criteria that relate to the evolution of the 
disorder could become redundant. 
The final component of the most recent criteria6 provides further clinical description 
of some of the original ‘variant’ forms, two of which — the early seizure onset variant now 
recognized as the CDKL5 disorder113 and the congenital variant, mostly caused by mutations 
in FOXG1114 — must now be considered only as Rett-related disorders111. The third atypical 
form, the Zappella or preserved speech variant107, is most often associated with an 
p.Arg133Cys mutation115 or a C-terminal deletion116 (FIG. 2). However, by additionally 
describing the forme fruste, late regression and male variants, Hagberg had already 
provided the best delineation of the full spectrum of clinical presentations117. As we reflect 
today on these early descriptors, we can see how well they fit with our current 
understanding of the relationships between genotype and phenotype.  
 
Overall severity and relationship with genotype. As early as 1987, the issue of the danger 
of masking the true clinical variation in RTT (BOXES 1,2) by the adoption of ‘artificial’ 
inclusion and exclusion criteria based on phenotype and not on cause was raised by the 
esteemed medical geneticist John Opitz118. Much later, and endorsing this concept in a 
different way, Hagberg acknowledged the wide clinical variation of what he called the 
“MECP2-deviant phenotypes,” with a spectrum ranging from the severe newborn 
encephalopathy in males to the female carrier mothers119. We now know, as Opitz might 
have predicted, that much of this spectrum relates to the type of genetic mutation, with the 
very mild variants often represented by individuals with C-terminal deletions in MECP2 
(REFS 119–121) (BOX 2). Although RTT is mostly considered to be a clinical diagnosis, a fine line 
remains between the naming of such individuals as “female forme fruste Rett syndrome 
variants”119 or as “people without Rett syndrome”121. 
The Australian register first provided the means to examine the spectrum of 
presentations in a total RTT population cohort using three previously published measures, 
designated as the Kerr122, Percy123 and Pineda124 scores125. Considerable variability in the 
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early regression period, current functioning and comorbidities, much of which was 
subsequently shown to relate to genotype, was demonstrated, and severity generally 
increased with age. 
Despite numerous small studies, it took time to accumulate adequate data to 
provide consistency in genotype–phenotype relationships. The two most seminal studies 
were published within months, the first using data from InterRett126, and the second from 
the US Natural History study127. Where comparable, the findings were broadly similar, with 
the most severe mutations being Arg270X, Arg255X and Arg168X, whereas Arg133Cys, 
Arg294X and C-terminal deletions produced less-severe phenotypes (BOXES 1,2; FIGS 2,3a). 
Overall, individuals with severe mutations were less likely to walk, retain hand use or use 
words, and tended to be diagnosed at an earlier age128 (FIGS 2,3b,4). A group with large 
deletions, which was not included in the initial InterRett study, was subsequently described 
separately, thereby confirming earlier US findings127 of phenotypic severity129 (FIGS 2,3a). A 
later publication also studied the C-terminal deletions — a milder group which, due to their 
comparatively later loss of skills and onset of stereotypies120, fit with the initial ‘late 
regression’ descriptor (BOX 2; FIGS 2,3a). Also of interest were the better growth 
parameters and increased likelihood of kyphosis in individuals with C-terminal deletions120. 
Information from these120,126,127,129 and other studies20 is enormously useful when 
considering prognosis in RTT, although it is clear that genotype is but one factor, and other 
factors, such as X-inactivation130, genetic modifiers131 and, possibly, environmental 
factors132, also have a role (BOX 2). 
 
Variation in functional abilities. The classic signs of RTT include severe functional 
impairments, usually necessitating substantial support in daily life. Subtle changes in 
development often precede the onset of regression109, which is characterized by either 
gradual or sudden loss of hand and communication skills, loss of balance, and development 
of hand steretoypies7,133. Patterns in the relationships between genotype and hand and 
gross motor skills have been observed126,134,135. Although cross-sectional studies suggest 
that motor function declines with increasing age, further longitudinal research is necessary 
to confirm or refute this idea. For example, some adults with RTT — probably those with a 
mutation associated with a milder phenotype — retain the capacity to walk136,137 (FIGS 
2,4a). Similarly for communication, those with milder mutations such as Arg133Cys or 
Arg306Cys are more likely to learn to babble or use words prior to regression, to regress at a 
later age, to retain some oral communication skills after regression, and to be diagnosed 
later115,128 (see FIGS 2,3b,4c).  
For individuals with RTT, a fundamental goal is to build the capacity for movement 
and communication in everyday life, and with a deeper understanding of motor deficits, the 
potential role of the enriched environment132, and technological advances in assisted 
communication systems, the capacity to respond is expanding. However, no relevant 
studies, beyond single or small case series138,139, have been conducted, so we do not fully 
understand what interventions are associated with favourable outcomes, and how 
treatments should be modified for variation in phenotype. 
 
Comorbidities and their management  
Epilepsy. Epilepsy is a particularly challenging comorbidity to study in RTT. Although the EEG 
is uniformly abnormal, typically from about 18 months of age140, this finding does not 
necessarily reflect seizure activity141. Moreover, some seizures seen during video–EEG 
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monitoring may not be recognized by caregivers as clinical events, and many events 
characterized by caregivers as seizures are not associated with EEG seizure discharges. these 
issues have contributed to difficulties in validating an epilepsy diagnosis and recording the 
seizure history for research, and probably to the comparative dearth of literature.  
With these caveats in mind, a number of investigations have been undertaken to 
study epilepsy in RTT. Epilepsy was diagnosed in 95% of a Swedish representative series 
(n = 53), although seizure frequency declined with age142. In one Australian study, the 
prevalence of epilepsy diagnosis was 81%, with a median age of onset of 4 years143. In 
another study, seizure rates were found to be generally higher in individuals with greater 
clinical severity and lower in those with Arg294X or Arg255X mutations or C-terminal 
deletions144. In recent years, three substantially sized studies have reported on epilepsy in 
RTT145–147. On average, just over 60% of cases were diagnosed with epilepsy, but in a US 
study145, a lower proportion had physician-verified seizures. Variations that were observed 
in relation to the effects of genotype (FIGS 2,5a) may have resulted from methodological 
differences, but in all three studies the mutation Thr158Met conferred some additional risk 
of epilepsy145–147. 
 
Growth and nutrition. Growth retardation was listed among the early supportive criteria for 
RTT5, with head growth deceleration occurring first, followed later by slowing of weight and 
height increase, and even of hand and foot growth 148. Although the exact underlying 
mechanism remains unclear149–151, a definite relationship with genotype exists120,150. Growth 
charts have been generated using cross-sectional and longitudinal data from 816 US cases, 
and the growth failure was found to be more pronounced in individuals with the more 
severe Thr158Met, Arg168X, Arg255X, Arg270X and large deletion mutations152 (FIGS 2,3a). 
Enteral support for individuals with RTT is common practice in developed countries. 
This approach is now being used in over one-quarter of cases153, particularly those with 
large deletion and Arg168X mutations (FIG. 2), with apparent benefits in terms of both 
growth parameters and parental satisfaction153. A large multinational group collated existing 
evidence and used expert opinion to provide guidance on the assessment and management 
of growth and feeding problems in RTT154. These published guidelines, which are available in 
user-friendly formats for clinicians and families, represent an important step in tackling this 
comorbidity154. 
 
Autonomic dysfunction. Individuals with RTT commonly exhibit abnormal breathing 
patterns, which are considered to be a manifestation of autonomic dysregulation. These 
problems generally present either as episodes of hyperventilation or breath-holding155,156. 
Abdominal bloating, which in rare cases can lead to gastric perforation157, is a common 
sequela, and may need alleviation through the release of air via a gastrostomy. Vasomotor 
disturbances causing cold and blue hands and feet were also identified as supportive clinical 
criteria for RTT5.  
Despite the intensive autonomic monitoring that is now undertaken in some 
European centres155, the prevalence and natural history of these disturbances, and their 
potential relationships with genotype, remain unknown. The literature on autonomic 
disturbance in humans with RTT is currently lagging behind that in animal models158. This 
knowledge gap is worrying, given that animal studies suggest the need for pharmacological 
interventions, and clinical trials of compounds that aim to reduce autonomic dysfunction 
are imminent. 
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Scoliosis. With the combination of neurological impairment and altered motor skills in 
individuals with RTT, the development of deformity such as scoliosis can be relentless. An 
early case series indicated that neurological signs were often asymmetrical, with the right 
side being more severely affected159, and subsequent larger studies found scoliosis to be a 
common deformity160,161. In the Australian study, 75% of girls developed scoliosis by 15 
years of age, with earlier onset in those with more severe mutations, such as Arg255X or 
large deletions160 (FIGS 2,5b). Scoliosis is usually progressive, particularly in children who are 
unable to walk, and in those with most common mutations other than  Arg306Cys160. The 
health implications can be profound, as scoliosis with a Cobb angle greater than 70° has 
particularly detrimental effects on respiratory health162.  
In response to a poor evidence base, an international group developed a set of 
clinical guidelines for the management of scoliosis in individuals with RTT, using the 
available literature but also drawing heavily on the literature for neuromuscular scoliosis. 
The consensus was that scoliosis should be regularly monitored and spinal fusion considered 
when the Cobb angle is greater than 50° (REF. 163). In a subsequent study, spinal fusion was 
associated with improved survival and, in individuals with early-onset scoliosis, a moderate 
reduction in frequency of severe respiratory tract infections164. This information is 
important for clinicians and families when weighing up the pros and cons of spinal fusion in 
individual girls and circumstances165. 
 
Sleep disturbances. Sleep disturbances have recently been considered as supportive criteria 
for RTT6,7, and their burden on the affected person and their family is often considerable. An 
early Australian study in individuals with RTT (n = 83) reported poor night-time sleep overall, 
and daytime naps that persisted with age166. Seizure disorders were associated with 
increased daytime sleep, and ability to walk was associated with less daytime sleep166. 
Further population-based research found a high prevalence of sleep problems, some of 
which (in particular, night laughing and screaming)  decreased with age167,168. The highest 
likelihood of sleep problems was observed in individuals with a large deletion, in whom 
night laughing was particurly common, or Arg294X167,168 (FIG. 2).  
A recent study, which used InterRett for ascertainment, surveyed parents or carers 
of 364 genetically confirmed cases aged 2–57 years169. Night waking was frequent and, 
consistent with previous research, individuals with the Arg294X mutation were most likely 
to have problems initiating and maintaining sleep169 (FIGS 2,5c). Individuals with epilepsy 
and/or limited mobility were more likely to have excessive somnolence, also consistent with 
earlier findings166.  
In one small clinical trial (n = 9), melatonin seemed to improve total sleep time and 
efficiency in individuals with poor sleep quality at baseline, without any adverse effects170. 
Considering the frequency of sleep dysfunction in RTT, and its impact on the child and their 
family, our evidence base for management remains remarkably sparse. 
 
Bone health. Unlike other comorbidities, adverse bone health has not been one of the 
supportive criteria for RTT. Susceptibility to osteopenia and fractures was first highlighted 
through US171 and Australian research172,173. Fracture risk was four times higher in 
individuals with RTT than in the general female population, and was specifically increased in 
those with Arg168X and Arg270X mutations173 (FIG. 2).  
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Several Danish174,175, US176,177 and Australian studies178,179 have investigated which 
particular bone parameters are most adversely affected in RTT, and their potential 
nutritional180 (for example, vitamin D status) environmental and genetic risk factors. Risk 
factors for fractures, such as genotype173 and use of certain antiepileptic medications181, did 
not always correlate exactly with those for low bone density, which also varied by outcome 
parameter and body site. For example, in comparison with other parameters, right femoral 
neck areal bone mineral density was particularly impaired with increasing age and lack of 
mobility178. A recent Danish study concluded that comparatively reduced levels of 
biochemical bone markers in RTT signified a a low bone turnover state182. Cross-study 
comparison has been hindered by non-representative and small sample sizes, often without 
longitudinal collection, as well as a lack of childhood population bone parameter norms and 
accommodation for decreased stature and different analytical methods.  
 MeCP2 deficiency has been shown to alter the biomechanical integrity of bone in a 
mouse model58,59, underlining the importance of understanding bone health in RTT. A set of 
guidelines for bone health was developed, which aimed to provide the best available 
evidence at time of publication183. We hope that these guidelines can soon be modified with 
results from clinical trials assessing the effectiveness of drugs such as bisphosphonates in 
RTT184. 
 
Therapeutic strategies 
The increased understanding of MeCP2 function and the availability of valid cellular and 
animal models has fuelled efforts to identify and develop therapeutic strategies for RTT185–
188. These efforts include targeting of the various brain systems and downstream cellular 
processes that are affected in RTT, as well as approaches that target the root cause of the 
disorder, namely, MeCP2 dysfunction185 (FIG. 6). 
Approaches that target MeCP2 at the level of the gene or protein to restore 
functional MeCP2 within the nervous system are appealing, as they have the potential to 
produce profound amelioration or reversal of symptoms, as demonstrated by reversal 
studies in mice43,44,189. Such approaches involve molecular and genetic manipulations, 
ranging from gene transfer190,191 and protein substitution to novel forms of DNA and RNA 
editing192. However, the level of MeCP2 in a given cell may be critical193, and restoring 
MeCP2 function without producing overexpression-related pathology is likely to be a 
significant challenge. Strategies targeting MECP2 typically require the development of 
completely novel molecules, which creates substantial uncertainty in terms of adequate 
brain delivery, safety and ensuing regulatory hurdles. The MeCP2 protein is a 
macromolecule with multiple functional domains, and restoration of normal function using 
small-molecule drugs is not considered to be practical. However, it might be possible to 
develop small molecules to act at the genomic level to reactivate the MECP2 allele on the 
inactive X chromosome194, or at the level of RNA to enable read-through of nonsense 
mutations195,196. 
In contrast to targeting of MECP2, pharmacological strategies that target 
downstream mechanisms in the pathogenic process can make use of small molecules that 
have already been developed or approved for other indications. Indeed, several drugs with 
proven efficacy in Mecp2 knockout mice have proceeded to clinical trials in patients with 
RTT185 (FIG. 6). However, such approaches do not address the underlying aetiology, and the 
lack of a dominant cellular process or pathway downstream of MeCP2 deficiency suggests 
that the benefits could be restricted to a subset of symptoms. The approaches that have 
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been developed to date can be broadly divided into three categories: pharmacological 
agents that affect major neurotransmitter systems in the brain, most notably glutamate, 
GABA, acetylcholine and monoamines (FIG. 6); drugs and trophic factors that promote brain 
growth and development, mostly by modulating the brain-derived neurotrophic factor 
pathway; and drugs that modulate other cellular processes known to be perturbed in 
models of RTT, such as energy metabolism and protein synthesis. 
 
Clinical trial design 
Clinical trials for rare disorders present many challenges, including mutation heterogeneity, 
variation in disease severity, and the pool of available participants. Additional 
considerations include the optimal time for intervention and the nature of trial design.185 
Important starting points include high-quality natural history data, and objective and robust 
outcome measures. Several clinical severity scores122,124,197 have worked well in studies of 
genotype–phenotype relationships126,127, but have not necessarily proved to be optimal as 
outcome measures in clinical trials198. For example, the Motor-Behavioral Assessment 
(MBA), which comprises 39 items scored with a five-point scale to describe clinical 
severity199, was used in one clinical trial198. However, this scale is poorly operationalized, 
with some items describing historical aspects of regression, and has never been validated. 
Similarly, the Rett Syndrome Behaviour Questionnaire200 was developed for the purpose of 
differentiating individuals with RTT from those with other causes of intellectual disability 
before genetic testing became available. This questionnaire has been used successfully in 
genotype–phenotype studies to assess some aspects of behaviour such as mood and 
anxiety137,201, but may not appropriately measure behaviour as an outcome in a clinical trial. 
A clear need exists for the further development of such instruments, and work is currently 
underway in this regard202. 
The Clinical Global Impression scales are clinician-rated, seven-point rating scales 
used to describe severity and change, and have recently been adapted to RTT for use in 
clinical trials203. This process has involved the development of seven category descriptors for 
the domains of communication, ambulation, hand use, use of eye contact, autonomic 
function, seizures, and attentiveness. Initial validation studies, including testing of 
responsiveness to change, are being undertaken203. More-sensitive measures of specific 
domains are also becoming available. For example, the 15-item Rett Syndrome Gross Motor 
Scale has undergone substantial validation suggesting capacity to demonstrate responses to 
interventions in the motor domain135. Wearable technologies have also been used for 
objective measurement of the patterns and regularity of respiratory and cardiac function in 
RTT in small observational studies156,204, and in a recent clinical trial198. Thus, some progress 
is being made in the important area of outcome measures, but much work is still needed to 
ensure that future clinical trials are able to provide the necessary answers. 
 
Global efforts to study a rare disorder 
Epidemiology. The Texas registry, which used multiple sources of ascertainment monitored 
with capture–recapture methods, was the first population-based registry to be established 
for RTT205. This registry provided a model for the Australian Rett Syndrome Database (FIG. 
1), which in 1997 reported that RTT had a cumulative incidence of 0.96 per 10,000 females 
by the age of 12 years206. Further studies in 2011 demonstrated that the cumulative 
incidence was increasing with age, and that the median age at diagnosis had fallen from 4.5 
years before 1999 to 3.5 years after this date207. 
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Infrastructures. The establishment of registries is a first step towards understanding the 
epidemiology, natural history and life expectancy of a rare disorder. Following Alison Kerr’s 
use of the British Paediatric Surveillance Unit to launch the British Isles RTT Survey in 1990 
(REF. 208), the Australian database (FIG. 1), established 3 years later, took advantage of the 
newly formed Australian Paediatric Surveillance Unit to ascertain cases206. The database has 
now been maintained for over two decades, and each additional year of follow-up increases 
its value137, providing the capacity to monitor children into adulthood and identify 
trajectories of functioning and comorbidities209. Population-based longitudinal follow-up 
with minimization of attrition is essential for studies of life expectancy, but is uncommon in 
the field of rare disorders. 
Genotype–phenotype investigations are, ideally, sourced from population-based 
sources210, but when mutations are rare or effect sizes are small, large sample sizes, 
sometimes through the aggregation of data from multiple sources, can provide much 
greater power. InterRett is one infrastructure that has served this purpose well by collecting 
questionnaire data internationally from both clinicians and families in over 50 countries 
since 2003 (REF. 211) (FIG. 1). Another such infrastructure, but based solely in the US, is  the 
Rare Disease Consortium Research Network for RTT145, which was initially established in 
2004 by Dr Alan Percy as a Natural History study212 (FIG. 1), and is now funded by the NIH. 
Although both of these data collections are likely by their nature to be highly selective, it 
has been possible to compare some characteristics of InterRett with an Australian 
population-based source213. The InterRett families were of a somewhat higher 
socioeconomic status than the Australian families, but the distributions of mutation type 
were broadly comparable .  
The original structure of the NIH-funded study involved the collection of data from 
clinic visits to inform the understanding of natural history. Currently, the main aim is to 
increase our understanding of the molecular basis of RTT, and to identify treatments that 
could improve functioning in affected individuals. Like InterRett, the European Rett 
Syndrome Database Network (EuroRett) combines data from multiple sources, and to date 
has mainly been applied to investigations on epilepsy147. RettBASE, the MECP2 Variation 
Database, has a different but valuable function, which is to catalogue the range of different 
genetic variants, both pathogenic and non-pathogenic, reported both in publications and 
from laboratories214. 
 
Role of advocacy groups. Advocacy groups have played a major part in the funding of 
infrastructures and RTT research. The main organization, which provides support and 
advocacy as well as funding, was established in 1984 as the International Rett Syndrome 
Association (IRSA)215. When commenting about the achievements of this organization, its 
founder, Kathy Hunter, wrote that “parents soon understood the critical part they must play 
in making sure that funds are available for research” and “they also understand the need for 
them to participate vigorously in research”216. 
 
International collaboration — challenges and accomplishments. International 
collaborations are vital for rare disease research. Over the years, however, differences have 
emerged at the international level in the understanding of RTT, and particularly in its 
associated terminology. Such differences can hamper progress. One example is a simple 
scoring system initially proposed by a UK researcher, which has not been widely adopted in 
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North America122. Another is the wide variation in autonomic monitoring and management, 
which is underpinned by limited evidence155. The Australian group has led a number of 
successful collaborative initiatives to develop guidelines for treatment of common RTT 
comorbidities. Often, in the absence of a strong evidence base, these initiatives depended 
on expert opinion garnered in a collegial fashion through the Delphi process154,163,183. 
 
Conclusions and future prospects  
In terms of the clinical presentation, many components of the original model of RTT 
proposed by Hagberg still ring true. Over the past 50 years, life expectancy for individuals 
with RTT has increased dramatically, partly because of changing attitudes and allocation of 
resources towards the health care of those with disability.  
The value of surgical treatment for scoliosis was first highlighted by Kerr et al., who 
reported positively on family perspectives of well-being 1 year after the fusion operation217. 
The benefits of this approach were further validated in recent studies, which used 
population-based data164,218. Enteral nutrition is now commonly available, at least in 
developed countries, and preliminary evidence indicates a positive impact on growth153. The 
beneficial effects of these management approaches may be reflected in the 71% survival 
rate at 25 years, reported in an Australian population cohort in 2010 (REF. 219), compared 
with 21% in Rett’s original cohort. Recent population data, using longitudinal follow-up over 
more than two decades, suggest that approximately 60% of individuals with RTT will survive 
to their late thirties137. This figure is considerably lower than the estimates of 50% at 50 
years from the North American Database220 (data derived from 50% response to 
questionnaires administered to IRSA family members) and 75% at 45 years from a 9-year 
follow-up of the US Natural History sample221. Both of the latter samples are large but select 
groups, and are likely to be more economically advanced than the general US population. 
Other societal changes include our passage into the digital age: the value of 
connecting families affected by RTT via the Internet was first demonstrated only 12 years 
ago222. Nowadays, social media sites are often the first port of call for families with a new 
diagnosis. Traditionally wary of patients seeking information from non-reputable sources, 
clinicians now appreciate the importance of this virtual peer support, especially for 
geographically isolated families affected by a rare disease.  
The greatest explosion of knowledge on RTT has occurred in the 16 years since the 
discovery of the genetic cause. During this period, US and Australian natural history studies 
and international databases have informed our understanding of genotype–phenotype 
relationships, and the comorbidities that occur in this disorder. We have learned much 
about the function of the MeCP2 protein, in particular, in its role as a regulator of gene 
expression and its interaction with other proteins. The reversal of neurological deficits in a 
mouse model in 2007 (REF. 43) raised hopes of a treatment that can restore MeCP2 
expression in humans.  
Although some progress has been made in improving clinical management, we still 
lack treatment options to resolve or substantially reduce the comorbidities of RTT. Many 
individuals — as well as their families — are adversely affected by poor sleep, a substantial 
proportion have refractory epilepsy, no evidence-based management options are available 
for autonomic breathing abnormalities, and the best methods to improve functional ability 
are not yet known. These are all important clinical challenges to address.  
The probability of translating promising preclinical outcomes to effective clinical 
treatments for nervous system disorders is modest, and expectations must be tempered 
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accordingly. However, the developing pipeline of putative therapies, and the coordinated 
efforts of clinicians, scientists and family organizations, together with increasing 
engagement of the biomedical industry, assure exciting developments ahead. 
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Key points  
 In the 50 years since its description by Andreas Rett, we have witnessed an explosion 
of knowledge about Rett syndrome (RTT) in relation to its genetic basis and clinical 
characteristics, and their interrelationships 
 Initially, the diagnosis of RTT was based solely on clinical criteria, but identification of 
its genetic cause has revolutionized this process, while presenting new challenges as 
we enter the era of next-generation sequencing 
 Mutations in the methyl-CpG-binding protein 2 (MECP2) gene were found to be 
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causative of RTT, accounting for fundamentally altered neurobiological pathways, 
and providing the stimulus to identifying pathways that can be manipulated 
therapeutically 
 The type of MECP2 mutation is associated with clinical severity, and influences many 
aspects of the phenotype, including functional abilities, onset of scoliosis, bone 
health, and sleep disturbances 
 Considerable progress has been made in understanding the natural history of RTT, 
leading to improvement in clinical management in selected areas, and changes in 
attitudes and allocation of health-care resources have increased life expectancy 
 The advancement in knowledge about RTT has been dependent on global efforts to 
study this disorder, including the establishment of database infrastructures, the 
input of advocacy groups, and the development of international collaborations 
 
Box 1 | Severe Rett syndrome phenotype 
JP is a 12-year-old girl with the Arg270X mutation in the methyl-CpG-binding protein 2 
(MECP2) gene (Supplementary information S1 (video)). She learned to sit at 9 months, but 
did not learn to walk. She did learn to say “mum”, “dad” and “nan”, but she found it difficult 
to grasp objects. Her mother was concerned about her poor developmental progress and 
jerky movements, and sought specialist advice when, at 14 months, her daughter suddenly 
stopped using words and developed hand stereotypies. Rett syndrome (RTT) was confirmed 
at the age of 2 years by the presence of a MECP2 Arg270X mutation, an early diagnosis that 
was consistent with her severe clinical presentation (FIGS 2–5).  
JP exhibited early regression of communication skills but no apparent loss of hand 
function. As a young child, she could grasp a large object but could not hold it — a feature 
that she still demonstrates today. JP illustrates many other features of RTT. Altered 
breathing patterns first developed at 18 months, and she still experiences daily 
hyperventilation and breath-holding with abdominal bloating. Epilepsy was diagnosed at the 
age of 4 years 8 months, although her seizures are currently well controlled. Since the age of 
9 years, she has been fed via a gastrostomy tube to ensure adequate fluids and nutrition, 
and to protect her respiratory health. Scoliosis was diagnosed at 5 years, and she 
underwent spinal fusion at 9 years. She has also sustained several long bone fractures in the 
lower limbs.  
JP’s sleep is regularly disturbed; she grinds her teeth, has a high pain tolerance and 
also has small and cold feet. She has experienced many episodes of bronchitis, although her 
respiratory health improved markedly after her spinal fusion. Unusually, JP recently 
developed inflammatory bowel disease. There are many limitations to her health and 
functioning, but she also lives a full life. She loves larking around with her family — her big 
eyes light up — and she enjoys school, music and swimming . 
 
Box 2 | Mild Rett syndrome phenotype 
KZ is a 13-year-old girl with a Pro389X mutation in the methyl-CpG-binding protein 2 
(MECP2) gene (Supplementary information S2 (video)). This teenage girl illustrates the mild 
phenotype of a C-terminal deletion, possibly further influenced by another genetic modifier.  
Initially, KZ progressed well, learning to walk at 12 months, and feeding herself and 
using four-word sentences as a toddler. However, speech delay, poor sleep and tremulous 
movements, which developed when she was 2 years old, raised some concerns. KZ’s mother 
began to suspect RTT when her daughter was 4 years old. After KZ developed epilepsy at 8 
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years of age, the possibility of RTT was dismissed because of her high level of gross motor 
skills (walking well across different terrains), good hand use and ability to maintain a 
conversation. In addition, her head growth had not decelerated. Her mother’s continued 
concern led to further genetic testing at 12 years, which demonstrated an MECP2 C-
terminal deletion (Pro389X). The lateness of diagnosis was consistent with her mild clinical 
presentation (FIGS 3–5). 
In retrospect, KZ experienced loss of finesse in her ability to turn pages when she 
was 2–3 years old, but showed no loss of communication skills. Her gait is mildly ataxic and 
she developed mild hand stereotypies at age of 6 years. She has had ongoing sleep 
disturbances since 3 years, her feet are cold and small, she has decreased sensitivity to pain, 
and displays substantial tremor, which is managed with trihexyphenidyl and a vagal nerve 
stimulator. Consistent with the C-terminal phenotype, her growth is good. A diagnosis for 
this young girl has provided important answers to her family.  
Beyond Rett syndrome, KZ is deeply involved in family, school and community life. 
She loves fun times with her father and competes in the Special Olympics in horse riding. 
Her diagnosis is an important part of her life, but is also compatible with learning and 
participation. 
 
Figure 1 | Timeline of key events and discoveries in Rett syndrome. 
 
Figure 2 | The MECP2 gene and Rett syndrome. The figure shows the structure of the 
methyl-CpG-binding protein 2 (MECP2) gene, and key MeCP2 protein domains implicated in 
Rett syndrome (RTT) pathogenesis. a | The two known mRNA isoforms, MECP2_e1 and 
MECP2_e2, generate two protein isoforms, which differ only at the extreme N-termini 
owing to the use of alternative translation start sites (bent arrows) and selective inclusion of 
exon 2 in the transcript. b | The MeCP2 protein contains distinct functional domains that 
are pertinent to RTT pathology: the methyl-CpG-binding domain (MBD), the transcriptional 
repression domain (TRD), NID, the NCOR–SMRT interaction domain (NID), and the nuclear 
localization signal (NLS). Missense mutations causing RTT predominantly cluster across the 
MBD and TRD/NID, whereas neutral variants tend to lie outside these domains. The 
locations of common RTT-causing point mutations are indicated, as is the region in which 
common C-terminal deletions occur. 
 
Figure 3 | Rett syndrome severity and age at diagnosis by mutation type. a | Association 
between clinical severity and methyl-CpG-binding protein 2 (MECP2) mutation type in 974 
(Pineda) and 776 (Percy) individuals with Rett syndrome (RTT). Data points are the mean 
scores adjusted for age and data source, with 95% confidence intervals.129 b | Age at 
diagnosis by mutation type in 1,040 individuals with RTT. Data points indicate the median 
age. Data from the Australian and International Rett Syndrome (InterRett) databases.  
 
Figure 4 | Functional abilities and mutation type in Rett syndrome. Graphs show the 
relationship between methyl-CpG-binding protein 2 (MECP2) mutation type and functional 
ability in individuals with Rett syndrome (RTT). Data were obtained from the International 
Rett Syndrome Database. a | Ambulation ability in 1,112 individuals with RTT. b | Hand use 
acquisition and loss in 1,097 individuals with Rett syndrome. c | Language ability and history 
in 1,046 individuals with RTT. 
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Figure 5 | Comorbidities and mutation type in Rett syndrome. a | Incidence of epilepsy 
onset by methyl-CpG-binding protein 2 (MECP2) mutation type in 560 individuals with Rett 
syndrome (RTT). Data points are the mean incidence, with 95% confidence intervals.145 b | 
Incidence of scoliosis diagnosis by MECP2 mutation type in 392 individuals with RTT. Data 
points are the mean incidence, with 95% confidence intervals.160 c | Relationship between 
sleep disturbances (disorders of initiating and maintaining sleep, or DIMS) and MECP2 
mutation type in 325 individuals with RTT. Data points are the mean DIMS score adjusted 
for age, seizure frequency and mobility, with 95% confidence intervals.168  
 
Figure 6 | Therapeutic strategies for Rett syndrome. Primary therapeutic strategies and 
compounds being investigated in preclinical animal models and in clinical trials (asterisks). 
IGF-1, insulin-like growth factor 1; MECP2, methyl-CpG-binding protein 2. 
 
